How to avoid concerns with the interpretation of two primary endpoints if significant superiority in one is sufficient for formal proof of efficacy
Open Access
- 22 May 2023
- journal article
- research article
- Published by Wiley in Pharmaceutical Statistics
- Vol. 22 (5) , 836-845
Abstract
Formal proof of efficacy of a drug requires that in a prospective experiment, superiority over placebo, or either superiority or at least non‐inferiority to an established standard, is demonstrated. Traditionally one primary endpoint is specified, but various diseases exist where treatment success needs to be based on the assessment of two primary endpoints. With co‐primary endpoints, both need to be “significant” as a prerequisite to claim study success. Here, no adjustment of the study‐wise type‐1‐error is needed, but sample size is often increased to maintain the pre‐defined power. Studies that use an at‐least‐one concept have been proposed where study success is claimed if superiority for at least one of the endpoints is demonstrated. This is sometimes also called the dual primary endpoint concept, and an appropriate adjustment of the study‐wise type‐1‐error is required. This concept is not covered in the European Guideline on multiplicity because study success can be claimed if one endpoint shows significant superiority, despite a possible deterioration in the other. In line with Röhmel's strategy, we discuss an alternative approach including non‐inferiority hypotheses testing that avoids obvious contradictions to proper decision‐making. This approach leads back to the co‐primary endpoint assessment, and has the advantage that minimum requirements for endpoints can be modeled flexibly for several practical needs. Our simulations show that, if planning assumptions are correct, the proposed additional requirements improve interpretation with only a limited impact on power, that is, on sample size.Keywords
This publication has 16 references indexed in Scilit:
- Key multiplicity issues in clinical drug developmentStatistics in Medicine, 2012
- Trimmed Weighted Simes' Test for Two One‐Sided Hypotheses With Arbitrarily Correlated Test StatisticsBiometrical Journal, 2009
- Simultaneous Confidence Regions Corresponding to Holm's Step‐Down Procedure and Other Closed‐Testing ProceduresBiometrical Journal, 2008
- Superiority Inferences on Individual Endpoints Following Noninferiority Testing in Clinical TrialsBiometrical Journal, 2008
- A 5-month, randomized, placebo-controlled trial of galantamine in ADNeurology, 2000
- Testing the Hypothesis that Matters for Multiple Primary EndpointsDrug Information Journal, 1996
- Exact t and F Tests for Analyzing Studies with Multiple Endpoints1996
- Multiple significance tests: the Bonferroni methodBMJ, 1995
- On a Heuristic Method of Test Construction and its use in Multivariate AnalysisThe Annals of Mathematical Statistics, 1953
- Testing Multiparameter HypothesesThe Annals of Mathematical Statistics, 1952